348 related articles for article (PubMed ID: 34200784)
1. Molecular Biomarkers in Idiopathic Pulmonary Fibrosis: State of the Art and Future Directions.
Stainer A; Faverio P; Busnelli S; Catalano M; Della Zoppa M; Marruchella A; Pesci A; Luppi F
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200784
[TBL] [Abstract][Full Text] [Related]
2. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Feng H; Zhao Y; Li Z; Kang J
Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
[TBL] [Abstract][Full Text] [Related]
3. Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone.
Lacedonia D; Correale M; Tricarico L; Scioscia G; Stornelli SR; Simone F; Casparrini M; Brunetti ND; Foschino Barbaro MP
Intern Emerg Med; 2022 Apr; 17(3):815-822. PubMed ID: 34787802
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of pulmonary fibrosis presenting with a usual interstitial pneumonia pattern on computed tomography in patients with myeloperoxidase anti-neutrophil cytoplasmic antibody-related nephritis: a retrospective single-center study.
Watanabe T; Minezawa T; Hasegawa M; Goto Y; Okamura T; Sakakibara Y; Niwa Y; Kato A; Hayashi M; Isogai S; Kondo M; Yamamoto N; Hashimoto N; Imaizumi K
BMC Pulm Med; 2019 Nov; 19(1):194. PubMed ID: 31675941
[TBL] [Abstract][Full Text] [Related]
5. Acute Exacerbation of Idiopathic Pulmonary Fibrosis.
Kishaba T
Medicina (Kaunas); 2019 Mar; 55(3):. PubMed ID: 30884853
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers and their potential functions in idiopathic pulmonary fibrosis.
Ni S; Song M; Guo W; Guo T; Shen Q; Peng H
Expert Rev Respir Med; 2020 Jun; 14(6):593-602. PubMed ID: 32187497
[No Abstract] [Full Text] [Related]
7. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
[TBL] [Abstract][Full Text] [Related]
8. Significance of molecular biomarkers in idiopathic pulmonary fibrosis: A mini review.
Chiba H; Otsuka M; Takahashi H
Respir Investig; 2018 Sep; 56(5):384-391. PubMed ID: 30030108
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers in idiopathic pulmonary fibrosis.
Drakopanagiotakis F; Wujak L; Wygrecka M; Markart P
Matrix Biol; 2018 Aug; 68-69():404-421. PubMed ID: 29408012
[TBL] [Abstract][Full Text] [Related]
10. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat.
Maher TM; Strek ME
Respir Res; 2019 Sep; 20(1):205. PubMed ID: 31492155
[TBL] [Abstract][Full Text] [Related]
11. Blood Biomarkers in Idiopathic Pulmonary Fibrosis.
Guiot J; Moermans C; Henket M; Corhay JL; Louis R
Lung; 2017 Jun; 195(3):273-280. PubMed ID: 28353114
[TBL] [Abstract][Full Text] [Related]
12. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
[TBL] [Abstract][Full Text] [Related]
13. Prognosis after acute exacerbation in patients with interstitial lung disease other than idiopathic pulmonary fibrosis.
Miyashita K; Kono M; Saito G; Koyanagi Y; Tsutsumi A; Kobayashi T; Miki Y; Hashimoto D; Nakamura Y; Suda T; Nakamura H
Clin Respir J; 2021 Mar; 15(3):336-344. PubMed ID: 33197284
[TBL] [Abstract][Full Text] [Related]
14. Potential biomarkers for diagnosis and disease evaluation of idiopathic pulmonary fibrosis.
Wang Q; Xie Z; Wan N; Yang L; Jin Z; Jin F; Huang Z; Chen M; Wang H; Feng J
Chin Med J (Engl); 2023 Jun; 136(11):1278-1290. PubMed ID: 37130223
[TBL] [Abstract][Full Text] [Related]
15. Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis.
Inchingolo R; Varone F; Sgalla G; Richeldi L
Expert Rev Respir Med; 2019 Jan; 13(1):39-51. PubMed ID: 30526140
[TBL] [Abstract][Full Text] [Related]
16. Comorbidity in idiopathic pulmonary fibrosis - what can biomarkers tell us?
Alfaro TM; Robalo Cordeiro C
Ther Adv Respir Dis; 2020; 14():1753466620910092. PubMed ID: 32167024
[TBL] [Abstract][Full Text] [Related]
17. Searching for airways biomarkers useful to identify progressive pulmonary fibrosis.
Soccio P; Moriondo G; Scioscia G; Leo V; Tondo P; Salerno L; Palange P; Barbaro MPF; Lacedonia D
BMC Pulm Med; 2023 Oct; 23(1):407. PubMed ID: 37884953
[TBL] [Abstract][Full Text] [Related]
18. Idiopathic pulmonary fibrosis: Diagnosis, biomarkers and newer treatment protocols.
Patel H; Shah JR; Patel DR; Avanthika C; Jhaveri S; Gor K
Dis Mon; 2023 Jul; 69(7):101484. PubMed ID: 36220705
[TBL] [Abstract][Full Text] [Related]
19. Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review.
Luppi F; Cerri S; Taddei S; Ferrara G; Cottin V
Intern Emerg Med; 2015 Jun; 10(4):401-11. PubMed ID: 25672832
[TBL] [Abstract][Full Text] [Related]
20. Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis.
Cameli P; Bergantini L; Salvini M; Refini RM; Pieroni M; Bargagli E; Sestini P
Nitric Oxide; 2019 Aug; 89():41-45. PubMed ID: 31054949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
